D. Sherrard

发表

HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

B. Kestenbaum, N. Weiss, S. Seliger, 2002, Kidney international.

Accelerated atherosclerosis in prolonged maintenance hemodialysis.

B. Scribner, D. Sherrard, B. Charra, 1974, The New England journal of medicine.

Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.

N. Weiss, A. Kausz, S. Emerson, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Serum phosphate levels and mortality risk among people with chronic kidney disease.

B. Kestenbaum, J. Sampson, S. Seliger, 2005, Journal of the American Society of Nephrology : JASN.

Aluminum toxicity.

D. Sherrard, 1983, Pediatrics.

Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.

Keith C. Norris, D. Sherrard, E. Slatopolsky, 1989, The New England journal of medicine.

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

S. Rosansky, L. Quarles, D. Sherrard, 2003, Journal of the American Society of Nephrology : JASN.

Effects of dietary caffeine on renal handling of minerals in adult women.

D. Sherrard, L. Massey, E. Bergman, 1990, Life sciences.

Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis.

A. Goldberg, W. Hazzard, J. Huttunen, 1979, The New England journal of medicine.

Prevalence of serum lipid abnormalities in chronic hemodialysis.

A. Goldberg, J. Brunzell, D. Sherrard, 1977, Metabolism: clinical and experimental.

The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study

D. Herndon, A. Sanford, D. Sherrard, 2005, Osteoporosis International.

Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.

K. Sullivan, G. Longton, S. Ott, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients.

Craig S. Wong, B. Kestenbaum, S. Seliger, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Calcium channel blocker use and mortality among patients with end-stage renal disease.

B. Kestenbaum, S. Seliger, C. Stehman-Breen, 2002, Kidney international.

Survival following parathyroidectomy among United States dialysis patients.

B. Kestenbaum, S. Schwartz, S. Seliger, 2004, Kidney international.

Aluminum‐associated bone disease in chronic renal failure: High prevalence in a long‐term dialysis population

D. Sherrard, D. Andress, N. Maloney, 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure.

D. Sherrard, D. Andress, D. M. Kates, 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Control of Renal Bone Disease

D. Sherrard, 1994 .

The spectrum of bone disease in end-stage renal failure--an evolving disorder.

Y. Pei, D. Sherrard, G. Segre, 1993, Kidney international.

The effect of prolonged fluoride therapy for osteoporosis: Bone composition and histology

J. Burnell, J. Wergedal, D. Sherrard, 1989 .

Metabolic bone disease in adults receiving long-term parenteral nutrition: longitudinal study with regional densitometry and bone biopsy.

S. Ott, D. Sherrard, E. Lipkin, 1993, JPEN. Journal of parenteral and enteral nutrition.

Manipulating the calcium receptor.

D. Sherrard, 2002, Journal of the American Society of Nephrology : JASN.

Quantitative histological studies on the pathogenesis of uremic bone disease.

J. Wergedal, D. Sherrard, D. Baylink, 1974, The Journal of clinical endocrinology and metabolism.

Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria.

M. Haussler, D. Sherrard, D. Baylink, 1977, The Journal of laboratory and clinical medicine.

Aluminum loading during total parenteral nutrition.

D. Sherrard, J. Coburn, M. Ament, 1982, The American journal of clinical nutrition.

Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism.

D. Sherrard, J. Brunzell, A. Goldberg, 1978, The Journal of clinical endocrinology and metabolism.

Blood pressure reductions during self-recording of home blood pressure.

D. Sherrard, K. D. Laughlin, L. Fisher, 1979, American heart journal.

Reversal of adynamic bone disease by lowering of dialysate calcium.

D. Sherrard, G. Hercz, Á. Haris, 2006, Kidney international.

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

H. Jüppner, D. Sherrard, W. Goodman, 2005, Kidney international.

High incidence of neoplasia in uremic patients receiving long-term dialysis. Cancer and long-term dialysis.

V. Farewell, D. Sherrard, A. Lindner, 1981, Nephron.

Secondary hyperparathyroidism complicated by parathyromatosis.

C. Stehman-Breen, D. Sherrard, N. Muirhead, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy.

H. Jüppner, D. Sherrard, W. Goodman, 2003, Kidney international.

Bone histomorphometry of renal osteodystrophy in diabetic patients

Keith C. Norris, J. Kopp, D. Sherrard, 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Early deposition of aluminum in bone in diabetic patients on hemodialysis.

J. Kopp, D. Sherrard, J. Coburn, 1987, The New England journal of medicine.

Evidence supporting a role of glucocorticoids in short-term bone loss in burned children

D. Herndon, J. Compston, D. Sherrard, 2004, Osteoporosis International.

Postheparin plasma triglyceride lipases in chronic hemodialysis: evidence for a role for hepatic lipase in lipoprotein metabolism.

A. Goldberg, W. Hazzard, J. Huttunen, 1979, Metabolism: clinical and experimental.

Control of clofibrate toxicity in uremic hypertriglyceridemia

A. Goldberg, J. Brunzell, D. Sherrard, 1977, Clinical pharmacology and therapeutics.

BONE DISEASE ASSOCIATED WITH TOTAL PARENTERAL NUTRITION

A. Norman, D. Sherrard, J. Coburn, 1980, The Lancet.

Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis.

D. Sherrard, S. Andreoli, J. Bergstein, 1984, The New England journal of medicine.

Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.

D. Sherrard, J. Boykin, J. V. Walker, 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.

S. Massry, A. Norman, D. Sherrard, 1974, Archives of internal medicine.

Further evidence supporting the phosphate leak hypothesis of idiopathic hypercalciuria.

M. Haussler, D. Sherrard, D. Baylink, 1978, Advances in experimental medicine and biology.

24,25(OH)2D3, bone formation, and bone resorption in vitamin D-deficient, azotemic rats

D. Sherrard, W. Goodman, D. Baylink, 1984, Calcified Tissue International.

Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study.

C. Stehman-Breen, D. Gillen, D. Sherrard, 2001, Journal of vascular surgery.

Chronic clofibrate therapy in maintenance hemodialysis patients.

D. Sherrard, J. Brunzell, L. Haas, 1980, Nephron.

Effect of high carbohydrate feeding with dextrose or sucrose on adipose tissue lipoprotein lipase activity and plasma triglyceride levels in hemodialysis patients.

A. Goldberg, D. Sherrard, J. Brunzell, 1979, The American journal of clinical nutrition.

Bone oxalate in a long-term hemodialysis patient who ingested high doses of vitamin C.

S. Ott, D. Sherrard, D. Andress, 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Evaluation of intravenous calcium as therapy for osteoporosis.

W. Nelp, D. Sherrard, C. Chesnut, 1973, The American journal of medicine.

Inert gas analysis of ventilation-perfusion matching during hemodialysis.

D. Sherrard, M. Hlastala, D. Ralph, 1984, The Journal of clinical investigation.

Bone disease in burn patients

D. Herndon, T. Rutan, D. Sherrard, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.

G. Howard, D. Sherrard, R. Turner, 1981, The Journal of biological chemistry.

Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury.

D. Chinkes, D. Herndon, D. Sherrard, 2007, Bone.

Risk of hip fracture among dialysis and renal transplant recipients.

B. Kestenbaum, N. Weiss, S. Seliger, 2002, JAMA.

Serum protein fractionation in normal pregnancy.

D. Sherrard, R. R. de Alvarez, J. Afonso, 1961, American journal of obstetrics and gynecology.

Avascular necrosis following bone marrow transplantation: a case-control study.

K. Sullivan, W. Leisenring, N. Weiss, 1998, Bone.

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.

Robert M. Williams, T. Hua, A. Pittenger, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients.

B. Kestenbaum, S. Seliger, C. Stehman-Breen, 2003, Kidney international.

Use of calcium carbonate as a phosphate binder in dialysis patients.

D. Sherrard, J. Coburn, J. Kraut, 1986, Mineral and electrolyte metabolism.

Development and reversibility of aluminum-induced bone lesion in the rat.

S. Ott, G. Howard, D. Sherrard, 1987, The Journal of laboratory and clinical medicine.

Specialty Conferenc Metabolic Causes of Nephrolithiasis

D. Sherrard, Discussant, 2022 .

Septic arthritis in hemodialyzed patients.

D. Sherrard, A. Lindner, F. Shen, 1980, Nephron.

Beta2-microglobulin deposition in bone in chronic renal failure

D. Sherrard, J. Coburn, D. Andress, 1991 .

Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function.

D. Sherrard, G. Segre, W. Goodman, 1993, Kidney international.

Simple Test for Hypercalciuria

G. Meadors, P. Miller, D. Sherrard, 1975 .

Renal osteodystrophy and aging.

D. Sherrard, 2009, Seminars in nephrology.

Interactions between dietary caffeine and calcium on calcium and bone metabolism in older women.

D. Sherrard, L. Massey, E. Bergman, 1994, Journal of the American College of Nutrition.

Vitamin D intoxication in an anephric child.

D. Sherrard, D. Baylink, F. Shen, 1975, Annals of internal medicine.

Reactivation of inhibited bone acid phosphatase and its significance in bone histomorphometry.

G. Howard, D. Sherrard, N. Maloney, 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Consequences of Low PTH Levels in Dialysis Patients

D. Sherrard, 1993 .

Dietary and behavioral risk factors for urolithiasis: potential implications for prevention.

R. Kronmal, J. Krieger, D. Sherrard, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Racial differences in bone mineral density and bone loss among end-stage renal disease patients.

C. Stehman-Breen, D. Sherrard, A. Walker, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia.

A. Norman, D. Sherrard, A. Brickman, 1983, The American journal of medicine.

Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism.

A. Norman, D. Sherrard, A. Brickman, 1981, Annals of internal medicine.

Regulation of glutamine metabolism in vitro by bicarbonate ion and pH.

D. Sherrard, D. Simpson, 1969, The Journal of clinical investigation.

Total body calcium and long-term calcium balance in chronic renal disease.

W. Nelp, D. Sherrard, C. Chesnut, 1973, The Journal of laboratory and clinical medicine.

Risk factors for renal osteodystrophy: A multivariant analysis

Y. Pei, D. Sherrard, G. Segre, 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy.

J. Kopp, D. Sherrard, J. Coburn, 1986, The Journal of clinical endocrinology and metabolism.

Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis.

D. Sherrard, I. Salusky, R. Fine, 1984, The Journal of pediatrics.

A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.

D. Sherrard, D. Andress, J. Antonsen, 1998, Kidney international.

Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients.

D. Sherrard, G. Segre, C. Greenwood, 1992, Kidney international.

Reversal of aluminum-related bone disease after substituting calcium carbonate for aluminum hydroxide.

D. Sherrard, J. Coburn, D. Andress, 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.

S. Ott, D. Milliner, D. Sherrard, 1986, Kidney international. Supplement.

Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure.

S. Ott, D. Sherrard, D. Andress, 1985, The New England journal of medicine.

The aplastic form of renal osteodystrophy.

D. Sherrard, G. Segre, G. Hercz, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Aplastic bone: a nondisease of medical progress.

D. Sherrard, 1995, Advances in renal replacement therapy.

Parathyroid hormone in aluminum bone disease: a comparison of parathyroid hormone assays.

S. Ott, D. Sherrard, D. Andress, 1986, Kidney international. Supplement.

Histological quantitation of aluminum in iliac bone from patients with renal failure.

S. Ott, D. Sherrard, J. Coburn, 1982, The Journal of laboratory and clinical medicine.

Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.

D. Sherrard, A. Brickman, F. Singer, 1980, Contributions to nephrology.

RENAL OSTEODYSTROPHY

D. Sherrard, 1964, Seminars in nephrology.

Improved bone formation in dialysis patients after substitution of calcium carbonate for aluminum gels.

Keith C. Norris, D. Sherrard, E. Slatopolsky, 1987, Transactions of the Association of American Physicians.

Aluminum and renal osteodystrophy.

D. Sherrard, 1986, Seminars in nephrology.

Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.

S. Ott, D. Milliner, D. Sherrard, 1984, Annals of internal medicine.

Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.

D. Sherrard, W. Demyer, S. Andreoli, 1985, The Journal of pediatrics.

A longitudinal study of lipid abnormalities in renal failure.

P. Wahl, D. Sherrard, L. Haas, 1983, Nephron.

Changes in bone histology after treatment with desferrioxamine.

S. Ott, D. Milliner, D. Sherrard, 1986, Kidney international. Supplement.

Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.

A. Norman, D. Sherrard, A. Brickman, 1977, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

Bone histologic response to deferoxamine in aluminum-related bone disease.

S. Ott, D. Sherrard, E. Slatopolsky, 1987, Kidney international.

Aluminum--much ado about something.

D. Sherrard, 1991, The New England journal of medicine.

Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy.

D. Sherrard, J. Coburn, D. Andress, 1987, The Journal of clinical endocrinology and metabolism.

Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome.

Keith C. Norris, D. Milliner, D. Sherrard, 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Pseudohyperparathyroidism. Syndrome associated with aluminum intoxication in patients with renal failure.

S. Ott, D. Sherrard, D. Andress, 1985, The American journal of medicine.

Toxic effects of aluminum in end-stage renal disease: discussion of a case.

Keith C. Norris, D. Sherrard, E. Slatopolsky, 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia.

D. Sherrard, F. Singer, K. Kurokawa, 1983, Kidney international.

The Role of Blood Pressure Regulation in Uremia

D. Sherrard, 1985 .

Calcimimetics in action.

D. Sherrard, 1998, Kidney international.

Periarticular tumoral calcinosis and hypercalcemia in a hemodialysis patient without hyperparathyroidism: a case report.

D. Sherrard, A. Tzamaloukas, M. Listrom, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases.

J. Wergedal, D. Sherrard, D. Baylink, 1975, The Journal of clinical endocrinology and metabolism.

The role of aluminum in renal osteodystrophy.

D. Sherrard, 1993, Mayo Clinic proceedings.

The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy.

S. Ott, D. Sherrard, J. Coburn, 1982, The New England journal of medicine.

Parathyroidectomy rates among United States dialysis patients: 1990-1999.

B. Kestenbaum, N. Weiss, S. Seliger, 2004, Kidney international.

Osteonecrosis in patients receiving dialysis: report of two cases and review of the literature.

D. Buskila, D. Sherrard, G. Hercz, 1990, The Journal of rheumatology.

Vasectomy is associated with an increased risk for urolithiasis.

R. Kronmal, J. Krieger, D. Sherrard, 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Thyroid function and lipids in patients with chronic renal disease treated by hemodialysis: with comments on the "free thyroxine index".

D. Sherrard, M. Kenny, J. Felicetta, 1979, Metabolism: clinical and experimental.

Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition.

S. Ott, D. Sherrard, J. Coburn, 1983, Annals of internal medicine.

Aluminum does not accumulate in teenagers and adults on prolonged parenteral nutrition containing free amino acids.

R. Recker, J. Tyrrell, D. Sherrard, 1986, JPEN. Journal of parenteral and enteral nutrition.

Bone aluminum and histomorphometric features of renal osteodystrophy.

S. Ott, D. Sherrard, A. Brickman, 1982, The Journal of clinical endocrinology and metabolism.

Bone crystal maturation in renal osteodystrophy in humans.

J. Burnell, J. Wergedal, D. Sherrard, 1974, The Journal of clinical investigation.

Metabolic bone disease of total parenteral nutrition: course after changing from casein to amino acids in parenteral solutions with reduced aluminum content.

S. Ott, D. Sherrard, E. Slatopolsky, 1988, The American journal of clinical nutrition.

Response to Drs Koo and Chesney

M. Shike, D. Sherrard, A. Alfrey, 1992 .

Aluminum induced bone disease: Clinical features

D. Sherrard, 1990 .

Recommendations for viral hepatitis.

D. Sherrard, 1986, Annals of internal medicine.

Dialysis Bone Disease

D. Sherrard, U. Binswanger, C. Rich, 1974 .

Bone biopsy to diagnose hyperoxaluria in patients with renal failure.

D. Sherrard, E. Cameron, N. Maloney, 1979, Annals of internal medicine.

Acute diphenylhydantoin intoxication.

D. Sherrard, H. Tenckhoff, R. Hickman, 1968, American journal of diseases of children.

Aluminum as a factor in the bone disease of long-term parenteral nutrition.

S. Ott, D. Sherrard, J. Coburn, 1982, Transactions of the Association of American Physicians.

Symptomatology, pathophysiology and treatment of the transurethral resection of the prostate syndrome.

H. T. Norris, D. Sherrard, J. Tremann, 1973, British journal of urology.

Advances in peritoneal dialysis.

D. Sherrard, H. Tenckhoff, F. Curtis, 1975, Kidney international. Supplement.

Renal osteodystrophy in diabetic patients.

Y. Pei, D. Sherrard, G. Segre, 1993, Kidney international.

Increased risk of hip fracture among patients with end-stage renal disease.

Craig S. Wong, S. Heckbert, N. Weiss, 2000, Kidney international.

Risk factors for hip fracture among patients with end-stage renal disease.

Craig S. Wong, S. Heckbert, N. Weiss, 2000, Kidney international.

Lithium-induced hyperparathyroidism: an alteration of the "set-point".

D. Sherrard, F. Shen, 1982, Annals of internal medicine.

Psychological correlates of survival on renal dialysis.

D. Sherrard, D. Calsyn, C. Freeman, 1977, The Journal of nervous and mental disease.

Carpal tunnel syndrome in chronic renal dialysis patients.

J. Delisa, D. Sherrard, W. Stolov, 1981, Archives of physical medicine and rehabilitation.

Hand dysfunction due to carpal tunnel syndrome: a common sequela of dialysis.

J. Delisa, D. Sherrard, S. Halter, 1979, Proceedings of the Clinical Dialysis and Transplant Forum.

Anthropometric measures and risk of death in children with end-stage renal disease.

Craig S. Wong, C. Stehman-Breen, D. Gipson, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Determinants of type and timing of initial permanent hemodialysis vascular access.

C. Stehman-Breen, D. Gillen, D. Sherrard, 2000, Kidney international.

Hypoalbuminemia and risk of death in pediatric patients with end-stage renal disease.

Craig S. Wong, C. Stehman-Breen, D. Gillen, 2002, Kidney international.

Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

Mei Wang, Mei Wang, Y. Pei, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Parenteral drug products containing aluminum as an ingredient or a contaminant: response to FDA notice of intent. ASCN/ASPEN Working Group on Standards for Aluminum Content of Parenteral Nutrition Solutions.

M. Shike, D. Sherrard, A. Alfrey, 1991, American Journal of Clinical Nutrition.

Aluminum-related osteodystrophy.

D. Sherrard, D. Andress, 1989, Advances in internal medicine.

Bone aluminum accumulation in hemodialysis patients: a longitudinal perspective.

J. Kopp, D. Sherrard, D. Andress, 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Renal Osteodystrophy: Past and Present

D. Sherrard, J. Antonsen, 1996 .

Assessment of a policy to reduce placement of prosthetic hemodialysis access.

T. Hatsukami, C. Stehman-Breen, D. Gillen, 2001, Kidney international.

Peritoneal dialysis fluid as a source of hepatitis antigen.

D. Sherrard, N. Gallagher, W. Goodman, 1981, Nephron.

Response to 'The low-calcium concentration of dialysate induced a marked increase of serum parathyroid hormone level in a continuous ambulatory peritoneal dialysis patient'.

D. Sherrard, G. Hercz, A. Haris, 2007, Kidney international.

Thirst, relative hypernatremia, and excessive weight gain in maintenance peritoneal dialysis.

D. Sherrard, D. Scollard, F. Shen, 1978, Transactions - American Society for Artificial Internal Organs.

Peritoneal dialysis, a feasible alternative.

D. Sherrard, A. Lindner, D. Scollard, 1973, Proceedings of the Clinical Dialysis and Transplant Forum.

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

G. Chertow, S. Moe, J. Cunningham, 2005, Kidney international.

BONE ALUMINIUM AND HISTOMORPHOMETRIC FEA-TURES OF RENAL OSTEODYSTROPHY

S. Ott, D. Sherrard, A. Brickman, 1982 .

Effects of 1-week head-down tilt bed rest on bone formation and the calcium endocrine system.

R T Whalen, R. Whalen, D. Sherrard, 1992, Aviation, space, and environmental medicine.

A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D.

A. Norman, D. Sherrard, A. Brickman, 1980, Contributions to nephrology.

Beta 2-microglobulin deposition in bone in chronic renal failure.

S. Onishi, D. Sherrard, J. Coburn, 1991, Kidney international.

Idiopathic hypercalciuria: The 'phosphate leak' hypothesis and the effects of oral phosphate supplement

D. Sherrard, D. Baylink, F. Shen, 1977 .

Peritoneal dialysis: a temporizing means for hemodialysis patients with subdural hematomas.

D. Sherrard, M. Mathews, G. Bidwell, 1977, Nephron.

Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease.

A. Sklar, D. Sherrard, H. Gopal, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Aluminum and TPN-related bone disease.

M. Shike, D. Sherrard, A. Alfrey, 1992, The American journal of clinical nutrition.

Burn-associated bone disease in sheep: roles of immobilization and endogenous corticosteroids.

D. Sherrard, D. Simmons, G. Klein, 1996, The Journal of burn care & rehabilitation.

Comparison of clinic and home blood pressure levels in essential hypertension and variables associated with clinic-home differences.

D. Sherrard, K D Laughlin, D J Sherrard, 1980, Journal of chronic diseases.

Metabolic causes of nephrolithiasis.

D. Sherrard, 1983, Western Journal of Medicine.

BONE DISEASE IN UREMIA

J. Wergedal, D. Sherrard, D. Link, 1972, Transactions - American Society for Artificial Internal Organs.

Renal Osteodystrophy in Pre-Dialysis Patients: Ethnic Difference?

D. Sherrard, S. Shin, Sung Jung Kim, 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Psychological assessment of renal dialysis patients using standard psychometric techniques.

D. Sherrard, D. Calsyn, C. Freeman, 1980, Journal of consulting and clinical psychology.

THIAZIDES AND RENAL STONES

D. Sherrard, 1981, The Lancet.

The effect of prolonged fluoride therapy for osteoporosis: bone composition and histology.

J. Burnell, J. Wergedal, D. Sherrard, 1990, Bone.

Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.

A. Norman, D. Sherrard, A. Brickman, 1980, Contributions to nephrology.

Interactions between dietary calcium and caffeine consumption on calcium metabolism in hypertensive humans.

D. Sherrard, L. Massey, E. Bergman, 1996, American journal of hypertension.

Nephrectomy for renovascular hypertension in azotemic patients.

D. Sherrard, J. Tremann, J. Haines, 1975, The Journal of urology.

Fluid and electrolyte physiology

D. Sherrard, M. Sherrard, 1980 .

Improved lipid profiles with bicarbonate dialysis.

D. Sherrard, S. Ahmad, L. Haas, 1980, Proceedings of the Clinical Dialysis and Transplant Forum.

Do everything you can.

D. Sherrard, 1990, Annals of internal medicine.